Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?

被引：0
|
作者：
Arthur Kavanaugh
机构：
[1] Allergy,Professor of Medicine and the Director of the Center for Innovative Therapy in the Division of Rheumatology
[2] and Immunology at the University of California San Diego,undefined
来源：
Nature Clinical Practice Rheumatology | 2006年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Tumor necrosis factor (TNF) inhibitors have proven highly effective in improving the signs and symptoms of rheumatoid arthritis, in inhibiting the progression of joint damage, and improving patients' quality of life. This Viewpoint will discuss the major concern relating to the actual use of TNF inhibitors in the clinic: their relatively high acquisition costs.
引用
收藏
页码：346 / 347
页数：1
相关论文
共 50 条
  • [31] Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
    Emery, Paul
    Vlahos, Bonnie
    Szczypa, Piotr
    Thakur, Mazhar
    Jones, Heather E.
    Woolcott, John
    Estrella, Paul V. Santos
    Rolland, Catherine
    Gibofsky, Allan
    Citera, Gustavo
    Sockalingam, Sargunan
    Marshall, Lisa
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (04) : 493 - 501
  • [32] Validation of a bioassay for predicting response to tumor necrosis factor inhibitors in rheumatoid arthritis
    Ho, Ching-Huang
    Silva, Andrea A.
    Giles, Jon T.
    Bathon, Joan M.
    Solomon, Daniel H.
    Liao, Katherine P.
    Ho, I-Cheng
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (06) : 1086 - 1087
  • [33] Monoamine oxidase inhibitors in rheumatoid arthritis - anti-tumor necrosis factor?
    Altschuler, EL
    INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 2000, 22 (11): : 1007 - 1008
  • [34] Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis
    Setoguchi, Soko
    Solomon, Daniel H.
    Weinblatt, Michael E.
    Katz, Jeffrey N.
    Avorn, Jerry
    Glynn, Robert J.
    Cook, E. Francis
    Carney, Greg
    Schneeweiss, Sebastian
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : 2757 - 2764
  • [35] ASSOCIATION BETWEEN RHEUMATOID FACTOR STATUS AND DISCONTINUATION OF TUMOR NECROSIS FACTOR INHIBITORS DUE TO INEFFECTIVENESS IN RHEUMATOID ARTHRITIS
    Ogawa, Yoshikazu
    Takahashi, Nobunori
    Kojima, Toshihisa
    Ishiguro, Naoki
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 722 - 723
  • [36] Medication Effectiveness with the Use of Tumor Necrosis Factor Inhibitors Among Texas Medicaid Patients Diagnosed with Rheumatoid Arthritis
    Oladapo, Abiola
    Barner, Jamie C.
    Lawson, Kenneth A.
    Novak, Suzanne
    Rascati, Karen L.
    Richards, Kristin M.
    Harrison, David J.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2014, 20 (07): : 657 - 667
  • [37] Reduced Cardiovascular Risk with Use of Methotrexate and Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis.
    Bozaite-Gluosniene, Rasa
    Tang, Xiaoqin
    Kirchner, H. Lester
    Antohe, Jana L.
    Morris, Stephanie J.
    Wasko, Mary Chester
    Bili, Androniki
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S279 - S280
  • [38] Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors
    Harrold, Leslie R.
    Reed, George W.
    Best, Jennie
    Zlotnick, Steve
    Persuitte, Gioia
    Kremer, Joel M.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [39] Cardiovascular Events in Early Rheumatoid Arthritis - Role of Tumor Necrosis Factor Inhibition
    Ljung, Lotta
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (11) : 2094 - 2096
  • [40] Tumor necrosis factor inhibitors in psoriatic arthritis
    Mantravadi, Santhi
    Ogdie, Alexis
    Kraft, Walter K.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 899 - 910
12345